Coagulation parameters in patients receiving dabigatran etexilate or rivaroxaban: Two observational studies in patients undergoing total hip or total knee replacement

Thrombosis Research

Volumn 127, Issue 5, 2011, Pages 457-465

  Freyburger, Geneviève ^a   MacOuillard, Gérard ^a   Labrouche, Sylvie ^a   Sztark, François ^a  

^a HÔPITAL PELLEGRIN   (France)

Author keywords

Coagulation; Dabigatran; Orthopedic surgery; Rivaroxaban; Thrombin Generation

Indexed keywords

AMIODARONE; CREATININE; D DIMER; DABIGATRAN ETEXILATE; RIVAROXABAN; THROMBIN;

ADULT; AGED; ANTICOAGULANT THERAPY; ARTICLE; BLOOD CLOTTING; BLOOD LEVEL; BODY WEIGHT; CONTROLLED STUDY; CREATININE CLEARANCE; DRUG BLOOD LEVEL; FEMALE; GENDER; HUMAN; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; PARTIAL THROMBOPLASTIN TIME; POSTOPERATIVE PERIOD; POSTOPERATIVE THROMBOSIS; PREOPERATIVE PERIOD; PRIORITY JOURNAL; PROTHROMBIN TIME; THROMBOSIS PREVENTION; TIME TO MAXIMUM PLASMA CONCENTRATION; TOTAL HIP PROSTHESIS; TOTAL KNEE REPLACEMENT;

AGED; AGED, 80 AND OVER; ANTICOAGULANTS; ARTHROPLASTY, REPLACEMENT, HIP; ARTHROPLASTY, REPLACEMENT, KNEE; BENZIMIDAZOLES; BLOOD COAGULATION; HUMANS; MALE; MIDDLE AGED; MORPHOLINES; PYRIDINES; THIOPHENES;

EID: 79955480110     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.thromres.2011.01.001     Document Type: Article

References (32)

1. B.I. Eriksson, L.C. Borris, R.J. Friedman, S. Haas, M.V. Huisman, and A.K. Kakkar RECORD1 Study Group. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty N Engl J Med 358 2008 2765 2775 (Pubitemid 351930851)
2. A.K. Kakkar, B. Brenner, O.E. Dahl, B.I. Eriksson, P. Mouret, and J. Muntz RECORD2 Investigators. Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial Lancet 372 2008 31 39
3. M.R. Lassen, W. Ageno, L.C. Borris, J.R. Lieberman, N. Rosencher, and T.J. Bandel Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty N Engl J Med 358 2008 2776 2786 (Pubitemid 351930852)
4. Turpie AG, Bauer KA, Davidson B, Comparison of rivaroxaban, an oral direct factor Xa inhibitor, and subcutaneous enoxaparin for thromboprophylaxis after total knee replacement (RECORD 4: a phase III study), Proceedings of the 9th EFORT Congress, Nice, May 30, 2008 Abst F85. Published in the Journal of Bone and Joint Surgery - British Volume, Vol 92-B, Issue SUPP-II, 329. Copyright © 2010 by British Editorial Society of Bone and Joint Surgery.
5. B.I. Eriksson, O.E. Dahl, N. Rosencher, A.A. Kurth, C.N. van Dijk, and S.P. Frostick RE-NOVATE Study Group. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, noninferiority trial Lancet 370 2007 949 956 (Pubitemid 47393577)
6. B.I. Eriksson, O.E. Dahl, N. Rosencher, A.A. Kurth, C.N. van Dijk, and S.P. Frostick RE-MODEL Study Group. Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the REMODEL randomized trial J Thromb Haemost 5 2007 2178 2185 (Pubitemid 47617868)
7. I. Melnikova The anticoagulant market Nat Rev Drug Discov 8 2009 353 354
8. S.E. Wolowacz, N.S. Roskell, J.M. Plumb, A. Clemens, H. Noack, and P.A. Robinson Economic evaluation of dabigatran etexilate for the prevention of venous thromboembolism in patients aged over 75 years or with moderate renal impairment undergoing total knee or hip replacement Thromb Haemost 103 2010 360 371
9. M. Holmes, C. Carroll, and D. Papaioannou Dabigatran etexilate for the prevention of venous thromboembolism in patients undergoing elective hip and knee surgery: a single technology appraisal Health Technol Assess 13 2009 S2:55-62
10. S.E. Wolowacz, N.S. Roskell, F. Maciver, S.M. Beard, P.A. Robinson, and J.M. Plumb Brenkel IJ. Economic evaluation of dabigatran etexilate for the prevention of venous thromboembolism after total knee and hip replacement surgery Clin Ther 31 2009 194 212
11. L. McCullagh, L. Tilson, C. Walsh, and M. Barry A cost-effectiveness model comparing rivaroxaban and dabigatran etexilate with enoxaparin sodium as thromboprophylaxis after total hip and total knee replacement in the irish healthcare setting Pharmacoeconomics 27 2009 829 846
12. G. Freyburger, P. Julien, and S. Labrouche Génération de thrombine calibrée et automatisée (CAT): intérêt d'un traitement du signal par un logiciel développé sur excel STV 20 2008 47 50 (Pubitemid 351268549)
13. G. Nowak The ecarin clotting time, a universal method to quantify direct thrombin inhibitors Pathophysiol Haemost Thromb 33 2003 173 183 (Pubitemid 39664135)
14. B.G. Tabachnick, and L.S. Fidell Using multivariate statistics 3rd ed 1996 Harper Collins New York
15. M.F. Hockin, K.C. Jones, S.J. Everse, and K.G. Mann A model for the stoichiometric regulation of blood coagulation J Biol Chem 277 2002 18322 18333 (Pubitemid 34952376)
16. G. Gerotziafas, I. Elalamy, F. Depasse, E. Perzborn, and M.M. Samama In vitro inhibition of thrombin generation, after tissue factor pathway activation, by the oral, direct factor Xa inhibitor rivaroxaban J Thromb Haemost 5 2007 886 888 (Pubitemid 46563600)
17. M.M. Samama, L. Le Flem, C. Guinet, G. Gerotziafas, and F. Depasse Three different patterns of calibrated automated thrombogram obtained with six different anticoagulants J Thromb Haemost 5 2007 2554 2556 (Pubitemid 350154370)
18. G.T. Gerotziafas, A.D. Petropoulou, E. Verdy, M.M. Samama, and I. Elalamy Effect of the anti-factor Xa and anti-factor IIa activities of low-molecular-weight heparins upon the phases of thrombin generation J Thromb Haemost 5 2007 955 962 (Pubitemid 46691725)
19. J. Stangier, K. Rathgen, H. Stähle, D. Gansser, and W. Roth The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects Br J Clin Pharmacol 64 2007 292 303 (Pubitemid 47283865)
20. D. Kubitza, M. Becka, B. Voith, M. Zuehlsdorf, and G. Wensing Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct factor Xa inhibitor Clin Pharmacol Ther 78 2005 412 421 (Pubitemid 41393676)
21. K.H. Liesenfeld, H.G. Schäfer, I.F. Trocóniz, C. Tillmann, B.I. Eriksson, and J. Stangier Effects of the direct thrombin inhibitor dabigatran on ex vivo coagulation time in orthopaedic surgery patients: a population model analysis Br J Clin Pharmacol 62 2006 527 537 (Pubitemid 44571573)
22. M.M. Samama, J.L. Martinoli, L. Le Flem, C. Guinet, G. Plu-Bureau, and F. Depasse Assessment of laboratory assays to measure rivaroxaban - an oral, direct factor Xa inhibitor Thromb Haemost 103 2010 815 825
23. J. Stangier Clinical parmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor dabigatran etexilate. Clin Pharmacokinet 47 2008 285 295 (Pubitemid 351508116)
24. V. Laux, E. Perzborn, D. Kubitza, and F. Misselwitz Preclinical and clinical characteristics of rivaroxaban: a novel, oral, direct factor Xa inhibitor Semin Thromb Hemost 33 2007 515 523 (Pubitemid 47105742)
25. J. van Ryn, J. Stangier, S. Haertter, K.H. Liesenfeld, W. Wienen, and M. Feuring Dabigatran etexilate-a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity Thromb Haemost 103 2010 1116 1127
26. J. Stangier, H. Stähle, K. Rathgen, W. Roth, and K. Shakeri-Nejad Pharmacokinetics and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor, are not affected by moderate hepatic impairment J Clin Pharmacol 48 2008 1411 1419
27. J. Stangier, B.I. Eriksson, O.E. Dahl, L. Ahnfelt, G. Nehmiz, and H. Stähle Pharmacokinetic profile of the oral direct thrombin inhibitor dabigatran etexilate in healthy volunteers and patients undergoing total hip replacement J Clin Pharmacol 45 2005 555 563 (Pubitemid 40562946)
28. http://www.ema.europa.eu/humandocs/PDFs/EPAR/pradaxa/emea-combined- h829en.pdf
29. W. Mueck, L.C. Borris, O.E. Dahl, S. Haas, M.V. Huisman, and A.K. Kakkar Population pharmacokinetics and pharmacodynamics of once- and twice-daily rivaroxaban for the prevention of venous thromboembolism in patients undergoing total hip replacement Thromb Haemost 100 2008 453 461
30. W. Mueck, B.I. Eriksson, K.A. Bauer, L. Borris, O.E. Dahl, and W.D. Fisher Population pharmacokinetics and pharmacodynamics of rivaroxaban - an oral, direct Factor Xa inhibitor - in patients undergoing major orthopaedic surgery Clin Pharmacokinet 47 2008 203 216
31. W. Mueck, M. Becka, D. Kubitza, B. Voith, and M. Zuehlsdorf Population model of the pharmacokinetics and pharmacodynamics of rivaroxaban - an oral, direct Factor Xa inhibitor - in healthy subjects Int J Clin Pharm Ther 45 2007 335 344 (Pubitemid 46895052)
32. J.M. Walenga, and C. Adiguzel Drug and dietary interactions of the new and emerging oral anticoagulants Int J Clin Pract 64 2010 956 967